Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Lung

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out what effects, good and/or bad, the treatments used in this study have on patients and their locally advanced, non-operable lung cancer with specific gene alterations (EGFR mutation or ALK rearrangement).

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

To find out if the study drug INCB059872 is safe and may have beneficial effects in people who have different types of cancer.

Status: Accepting New Patients
Principal Investigator: Young Chae

Parallel Proof Of Concept Phase 2 Study Of Nivolumab And Metformin Combination Treatment In Advanced Non-Small Cell Lung Cancer With And Without Prior Treatment With PD-1/PD-L1 Inhibitors

The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy. We will also be looking at the safety of the combination.

Status: Accepting New Patients
Principal Investigator: Young Chae

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888_ Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out what effects (good and/or bad) Veliparib has, when added to standard combination therapy of Radiation, Carboplatin, and Paclitaxel, on participants and their non-small cell lung cancer.

Status: Accepting New Patients
Principal Investigator: Victoria Villaflor

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

The purpose of this study is to evaluate and compare the effects (good and/or bad) of different targeted study drugs to the standard chemotherapy.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

The main goals of the research study are to determine the highest safe dose of veliparib in combination (given together) with carboplatin and etoposide, to understand how the body absorbs and handles veliparib when given together with carboplatin and etoposide, and to evaluate the safety and tolerability of veliparib when taken without the chemotherapy combination.

Status: Accepting New Patients
Principal Investigator: Young Chae

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

To determine the efficacy of MGCD265 in the selected patient population.

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with Or without Hippocampal Avoidance In Patients with Brain Metastases

To determine whether minimizing radiation dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation can decrease the risk of cognitive side effects after radiation therapy to the brain to using the usual whole-brain radiation plus memantine (a drug that can also reduce cognitive side effects of brain radiation).

Status: Accepting New Patients
Principal Investigator: Timothy Kruser

SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The main purpose of this study is to find out more about the side effects of MM-121 when combined with docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM-121 with docetaxel or pemetrexed.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Thu - October 19, 2017 - 06:45 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.